UK +44 (0)1223 491486      USA toll free 1-866 877 2185

Search
Generic filters
11 03, 2022

List prices frozen until 2023

By |2022-03-11T16:14:30+00:00March 11th, 2022|news, press release|Comments Off on List prices frozen until 2023

Despite the ongoing challenges faced by the whole industry, we are demonstrating our commitment to supporting stem cell researchers by freezing our prices until January 1st, 2023. Furthermore, we will include free shipping on all orders moving forward.

10 09, 2021

Qkine earns ISO9001: 2015 certification for protein R&D and manufacture facilities in Cambridge, UK

By |2021-09-10T18:53:50+00:00September 10th, 2021|awards, cellular agriculture, news, press release, quality|Comments Off on Qkine earns ISO9001: 2015 certification for protein R&D and manufacture facilities in Cambridge, UK

Qkine certified ISO9001: 2015 for its quality management system encompassing R&D, manufacturing, and operations in Cambridge, UK. Qkine supplies growth factors and cytokines to the fast-moving stem cell, organoid and emerging cultured meat sectors. Exceptional product quality and scientific support are crucial to customer's business processes and experimental outcomes.

26 07, 2021

Qkine and Enantis sign licensing deal for hyperstable FGF2-STAB®

By |2021-07-26T08:14:57+00:00July 26th, 2021|animal-free, cellular agriculture, news, press release, protein engineering, protein science, stem cells|Comments Off on Qkine and Enantis sign licensing deal for hyperstable FGF2-STAB®

Qkine and Enantis have concluded a global licensing deal for Enantis’s patented FGF2-STAB® technology. FGF2-STAB® is a hyperstable form of FGF-2 (bFGF), a core reagent for stem cell culture. FGF2-STAB (FGF2-G3) does not degrade in culture media for enhanced weekend-free stem cell culture media and advanced chemically defined systems, such as those needed in the cultured meat industry.

21 07, 2020

Rob Nixon joins Qkine as Head of Commercial and Dr Cassie Doherty is appointed to the board

By |2020-12-08T16:06:23+00:00July 21st, 2020|news, press release|Comments Off on Rob Nixon joins Qkine as Head of Commercial and Dr Cassie Doherty is appointed to the board

Cambridge, UK 21 July 2020: Qkine – a specialist developer and manufacturer of proteins for stem cell, organoid and regenerative medicine applications – is delighted to announce the appointment of Rob Nixon to its management team as Head of Commercial and Dr Cassie Doherty, Investment Director at Parkwalk, to its board. With years of [...]

8 06, 2020

Qkine secures £1.5M series A funding from leading life science investors

By |2022-02-07T11:50:51+00:00June 8th, 2020|news, press release|Comments Off on Qkine secures £1.5M series A funding from leading life science investors

Qkine secures £1.5M series A funding from leading life science investors Cambridge, UK 08 June 2020: Qkine – a specialist developer and manufacturer of proteins for stem cell, organoid and regenerative medicine applications – today announced the successful closure of a £1.5M series A investment round to accelerate the global [...]

3 06, 2019

Qkine secures additional £550K to extend development of R&D pipeline and accelerate commercialisation of product portfolio

By |2022-02-07T11:49:25+00:00June 3rd, 2019|news, press release|Comments Off on Qkine secures additional £550K to extend development of R&D pipeline and accelerate commercialisation of product portfolio

Qkine secures additional £550K to extend development of R&D pipeline and accelerate commercialisation of product portfolio Cambridge, UK 03 June 2019: Qkine, specialist manufacturer of proteins for stem cell, organoid and regenerative medicine applications, has closed a further round of investment. The £550K funding round was led by Cambridge Enterprise [...]

23 04, 2018

Qkine backed by Cambridge Enterprise and a quintet of angels

By |2022-02-07T11:31:33+00:00April 23rd, 2018|news, press release|Comments Off on Qkine backed by Cambridge Enterprise and a quintet of angels

Qkine backed by Cambridge Enterprise and a quintet of angels University of Cambridge spin-out Qkine has closed its seed investment round supported by Cambridge Enterprise, the commercialisation arm of the University, and a team of five angels led by Jim Warwick. The amount is undisclosed. Qkine is a specialist manufacturer [...]

Title

Go to Top